ODYSSEY OUTCOMES trial
a. Reduced major adverse cardiovascular events (MACE), myocardial infarction (MI) and ischemic stroke
b. Was associated with a lower rate of all-cause death
c. Was safe and well-tolerated over the duration of the trial.
Lipoprotein(a) [Lp(a)] reduction in persons with CVD:
a. Subcutaneous injection of an siRNA (SLN360) targeting mRNA for the LPA gene lowered Lp(a) up to 98%.
b. >70% and >80% reductions in Lp(a) persisted for 150 days after the 300 mg and 600 mg doses.
c. The highest doses reduced LDL-C and apoB by 20% to 30%.
d. There were no major safety issues, although low-grade, transient, dose-dependent injection site reactions occurred. These findings support the further development of this therapy.
PCSK9 Inhibitor therapy with Inclisiran
a. LDL-C variability within individuals is practically eliminated.
b. Injection burden reduced substantially.
c. Sustained effect between infrequent injections
d. Opportunity to improve patient adherence.
2. Phase II and the ongoing Phase III studies have robust long-term efficacy with no safety issues.
Subscribe To Our Newsletter
Filter out the noise and nurture your inbox with health and wellness advice that's inclusive and rooted in medical expertise.
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
Please update your details